A nomogram to predict loco-regional control after re-irradiation for head and neck cancer |
| |
Authors: | Nadeem Riaz Julian C. Hong Eric J. Sherman Luc Morris Matthew Fury Ian Ganly Tony J.C. Wang Weji Shi Suzanne L. Wolden Andrew Jackson Richard J. Wong Zhigang Zhang Shyam D. Rao Nancy Y. Lee |
| |
Affiliation: | 1. Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, United States;2. Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, United States;3. Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, United States;4. Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, United States;5. Department of Radiation Oncology, Columbia University, New York, United States |
| |
Abstract: | Background and purposeLoco-regionally recurrent head and neck cancer (HNC) in the setting of prior radiotherapy carries significant morbidity and mortality. The role of re-irradiation (re-RT) remains unclear due to toxicity. We determined prognostic factors for loco-regional control (LRC) and formulated a nomogram to help clinicians select re-RT candidates.Material and methodsFrom July 1996 to April 2011, 257 patients with recurrent HNC underwent fractionated re-RT. Median prior dose was 65 Gy and median time between RT was 32.4 months. One hundred fifteen patients (44%) had salvage surgery and 172 (67%) received concurrent chemotherapy. Median re-RT dose was 59.4 Gy and 201 (78%) patients received IMRT. Multivariate Cox proportional hazards were used to identify independent predictors of LRC and a nomogram for 2-year LRC was constructed.ResultsMedian follow-up was 32.6 months. Two-year LRC and overall survival (OS) were 47% and 43%, respectively. Recurrent stage (P = 0.005), non-oral cavity subsite (P < 0.001), absent organ dysfunction (P < 0.001), salvage surgery (P < 0.001), and dose >50 Gy (P = 0.006) were independently associated with improved LRC. We generated a nomogram with concordance index of 0.68.ConclusionRe-RT can be curative, and our nomogram can help determine a priori which patients may benefit. |
| |
Keywords: | Re-irradiation Head and neck cancer Intensity modulated radiation therapy Recurrent head and neck cancer |
本文献已被 ScienceDirect 等数据库收录! |
|